MALAYSIA INFLUENZA SURVEILLANCE PROTOCOL

Full text

1
MALAYSIA INFLUENZA SURVEILLANCE PROTOCOL
TABLE OF CONTENTS
Introduction ....... 3
The Guiding Principles ....... 3
Objectives ............................... 4
The Case Definitions
a) Influenza-Like Illness (ILI) ....... 4
b) Severe Acute Respiratory Infection (SARI) ........ 4
The Sentinel Sites ........ 5
Methodology
a) Epid / Clinical-Based Influenza Surveillance ..... 6
b) Laboratory-Based Influenza Surveillance ........ 10
Data Analysis and Reports .. 17
The Roles and Responsibilities .. 18
The National Influenza Surveillance Coordinator .. 20
Annexes
a) Annex 1: Daily Aggregated Data Form For ILI (For Health Clinic Use) ..... 21
b) Annex 2: Daily Aggregated Data Form For SARI (For Ward Use) ...... 22
c) Annex 3: Daily Aggregated Data Form For SARI (For Public Health Unit Use) .. 23
d) Annex 4: Sampling Methodology  24
e) Annex 5: Method for Collection of Respiratory Specimens ........ 25
f) Annex 6: Borang Permohonan Ujian Makmal .. 28
Coordinated by:
Surveillance Sector
Disease Control Division
Ministry of Health Malaysia
November 2015

2
EDITORIAL BOARD
ADVISORS:
Dr. Chong Chee Kheong
Director of Disease Control Division, MOH Malaysia
Dr. Norhayati binti Rusli
Deputy Director of Disease Control Division (Surveillance), MOH Malaysia
MEMBERS:
Dr. Khebir Verasahib
Director of National Public Health Laboratory (NPHL) Sungai Buloh
Ministry of Health (MOH) Malaysia
Dr. Zainudin bin Abdul Wahab
Head of Zoonosis Sector
Disease Control Division, MOH Malaysia
Dr. Zainah binti Saat
Head of Virology Unit
Institute for Medical Research (IMR), MOH Malaysia
Dr. Wan Noraini binti Wan Mohamed Noor
Head of Surveillance Sector
Disease Control Division, MOH Malaysia
Dr. Ravindran Thayan
Research Officer (Virology)
Institute for Medical Research (IMR), MOH Malaysia
Dr. Faridah binti Mohd Amin
Principal Assistant Director
National Public Health Laboratory (NPHL) Sungai Buloh, MOH Malaysia
Ms. Norizah binti Ismail
Science Officer
National Public Health Laboratory (NPHL) Sungai Buloh, MOH Malaysia
Mr. Selvanesan Sengol
Science Officer
National Public Health Laboratory (NPHL) Sungai Buloh, MOH Malaysia
SECRETARIAT:
Dr. Zuhaida binti A. Jalil
Principal Assistant Director (Surveillance)
Disease Control Division, MOH Malaysia
Dr. Sukhvinder Singh Sandhu
Principal Assistant Director (Surveillance)
Disease Control Division, MOH Malaysia
Ms. Farahdilla binti Abu Bakar
Environmental Health Officer (Surveillance)
Disease Control Division, MOH Malaysia

3
1. INTRODUCTION
Influenza is an acute contagious viral respiratory disease characterized by fever,
cough, sore throat, headache, myalgia, prostration and coryza. Whereby, symptoms
and signs differ according to the age of those infected.
The influenza virus spreads rapidly around the world in seasonal epidemics. In
temperate regions, seasonal influenza typically occurs every year in the late fall or
winter. In tropical and subtropical regions, the seasonality of influenza is less clearly
defined, with background activity occurring year-round.
Influenza infection is caused by RNA viruses belonging to the Orthomyxoviridae
family. There are three types of influenza viruses; A, B and C, and humans can be
infected with all three types. Influenza A and B viruses cause epidemic disease in
humans and type C viruses usually cause a mild, cold-like illness.
At unpredictable intervals, however, novel influenza viruses emerge with a key
surface antigen (the haemagglutinin) of a totally different sub-type from strains
circulating the year before. The reality of a pandemic threat is further highlighted by
the fact that limited, non-sustained H5N1 virus transmission between humans has
been reported. These incidents serve to emphasize the importance of surveillance
as the foundation for efforts to understand and control influenza disease.
2. THE GUIDING PRINCIPLES
The development of this document, following revision of the previous document (i.e.
Malaysia Influenza Surveillance System; 2004) was guided by the following
principles:
a) Recent publication of the WHO Global Epidemiological Surveillance
Standards for Influenza in 2013, which describes revised global standards for
a minimal basic respiratory disease surveillance system for the monitoring of
influenza.
b) Revised, standard and reliable case definitions addressed in this document
would allow for the collected data to be compared across time, within
Malaysia and regionally.
c) Creation of a routine surveillance system will establish infrastructure such as
systems for specimen transport and testing, systems for information gathering
and analysis, and a formation of trained personnel whom are familiar with
influenza and respiratory disease epidemiology.

4
d) The routine data collected in a sustainable sentinel surveillance system is the
most efficient approach to collect high-quality data in a timely way.
3. OBJECTIVES
a) To establish seasonal thresholds and reliable national trend data for
influenza-like illness (ILI) and severe acute respiratory infection (SARI).
b) To describe the antigenic character and genetic makeup of circulating viruses.
c) To provide data that can contribute to the estimation of the burden of severe
respiratory disease associated with influenza and other respiratory pathogens.
d) To provide platform for surveillance that includes additional common
respiratory pathogens that may be of national interest.
4. THE CASE DEFINITIONS
There are two (2) case definitions in this guidance document. Case definitions for
influenza-like illness (ILI) are for milder disease presented and managed in the
primary care / out-patient setting. The case definition for severe acute respiratory
infection (SARI) is provided for use in the in-patient hospital settings. The
combination of data from ILI and SARI patients should provide a description of a
broad range of medically-attended influenza cases.
a) Case definition for influenza-like illness (ILI):
An acute respiratory infection with:
• Measured fever of ≥ 38
o
C;
• and cough;
• with onset within the last ten (10) days.
Notes:
Taking into consideration the work process involved in capturing data at the sentinel sites, it is
recommended for a diagnosis of upper respiratory tract infection (URTI) to be used as the
proxy for ILI case selection.
b) Case definition for severe acute respiratory infection (SARI):
An acute respiratory infection with:
• History of fever or measured fever of ≥ 38
o
C;
• and cough;
• with onset within the last ten (10) days;
• and requires hospitalization.

5
Notes:
Taking into consideration the work process involved in capturing data at the sentinel sites, it is
recommended for a diagnosis of pneumonia, bronchitis or bronchiolitis to be used as the proxy
for SARI case selection.
5. THE SENTINEL SITES
A sentinel surveillance system is formed by one or more designated health care
facilities that routinely and consistently collect epidemiologic information and
laboratory specimens from patients presenting with an illness consistent with a
specified case definition. Sentinel surveillance systems provide an efficient way to
obtain high quality data on relatively common conditions from a manageable number
of locations. In this way, the objectives of influenza surveillance can be met more
easily and at lower cost, than with universal surveillance.
Therefore, the number of the sentinel sites was revised (mainly based on their
performance within the previously existing Malaysia Influenza Surveillance System;
MISS) and the following sentinel sites were identified nationwide:
a) Sentinel Sites for Influenza-Like Illness (ILI) Surveillance
No. State Facility
1. Kedah Bandar Alor Setar Health Clinic
2. Pulau Pinang Seberang Jaya Health Clinic
3. Perak OPD of Kuala Kangsar Hospital
4. Selangor Salak Tinggi Health Clinic
5. WPKL & Putrajaya Batu Health Clinic
6. Negeri Sembilan Nilai Health Clinic
7. Melaka Peringgit Health Clinic
8. Johor Mahmoodiah Health Clinic
9. Pahang Lanchang Health Clinic
10. Terengganu Hiliran Health Clinic
11. Kelantan Bandar Kota Bharu Health Clinic
12. Sarawak
•
Jalan Masjid Health Clinic
• Miri Health Clinic
13. Sabah
•
Luyang Health Clinic
• Sandakan Health Clinic
b) Sentinel Sites for Severe Acute Respiratory Infection (SARI) Surveillance
No. State Facility
1. Kedah Sultanah Bahiyah Hospital, Alor Setar
2. Selangor Tengku Ampuan Rahimah Hospital, Klang
3. WPKL & Putrajaya Kuala Lumpur Hospital

6
4. Melaka Melaka Hospital
5. Johor Sultanah Aminah Hospital, Johor Bahru
6. Kelantan Raja Perempuan Zainab II Hospital, Kota Bharu
7. Sarawak Sarawak General Hospital, Kuching
8. Sabah
•
Queen Elizabeth Hospital, Kota Kinabalu
• Likas Women’s And Children’s Hospital
6. METHODOLOGY
The surveillance activities for influenza, including both the clinical-based and
laboratory-based are carried out throughout the year as Malaysia being a tropical
country, has no well-defined seasonality of influenza.
a) Epidemiological / Clinical-Based Influenza Surveillance
Data collected daily at the sentinel sites (both for ILI and SARI cases) using
respective format in ‘Annex 1’, ‘Annex 2’ and ‘Annex 3’. The flow of data related
to influenza surveillance activity and details of the relevant tasks involved, are
shown in ‘Figure1’ and ‘Table 1’ respectively.

7
Figure 1: Flow of Data Related to Influenza Surveillance Activity
Note:
Flow for epid data
Flow for clinical specimens
To send the virus isolates to WHO Collaborating
Centre (via IMR) for further characterization of
the virus in a timely manner
Daily
Daily
Weekly
Weekly
Health Clinics
(Sentinel sites for ILI):
Data collected daily
Hospitals
(Sentinel sites for SARI):
Data collected daily
Respective District Health
Office (PKD)
Respective State Health
Department (JKN)
Surveillance Section
Disease Control Division,
MOH Malaysia
National Public Health
Laboratory (NPHL)
Sungai Buloh, Selangor
Virology Unit
Institute of Medical
Research (IMR)
WHO Collaborating
Centre for Influenza
Weekly
Weekly
Daily
Daily

8
Table 1: Details of Task / Activity Related to Influenza Surveillance Activity
Task / Activity
Responsibility
Timeframe
Health Clinics (as the sentinel sites for ILI)
(A) Epid / Clinical-Based Surveillance:
• Establishment of a working diagnosis
• Treat accordingly
• Referral to hospital (if necessary)
• Recorded within the ‘Daily Aggregated
Data Form For ILI’ (refer Annex 1)
(B) Laboratory-Based Surveillance:
• To collect 5 specimens per site per week
(i.e. 3 adults and 2 children) by doctors or
trained medical personnel
• The patient is systematically chosen for
testing and meets the case definition for
ILI – refer ‘Annex 4’ for the sampling
methodology
• To use the ‘Laboratory Request Form’
(Annex 6)
The Assistant Medical
Officer:
• To complete the ‘Daily
Aggregated Data Form
For ILI’ (refer Annex 1)
• To send Annex 1 to the
respective District
Health Office (PKD)
• To compile both epid
data (Annex 1) and lab
data (as per Annex 6)
for future reference
The Medical Officer /
Assistant Medical Officer /
Nursing Personnel:
• To collect the clinical
specimens as guided
by the established
procedures (Annex 5)
The Medical Laboratory
Technologist:
• To ensure proper
storage and transport
of the collected
samples
• To send the samples
collected to NPHL
Sungai Buloh, in
accordance with the
procedures established
• By the end of
the clinic’s
operation hours
• By 9:00 am of
the next
working day
• Continuously
• Based on the
specified
schedule
• Continously
• Weekly
Hospitals (as the sentinel sites for SARI)
(A) Epid / Clinical-Based Surveillance:
• Establishment of a working diagnosis
• Treat accordingly
• Recorded within the ‘Daily Aggregated
Data Form For SARI’ (refer Annex 2) –
involving data both from Medical and
Pediatric Ward, including the respective
ICUs
The nursing personnel:
• To complete the ‘Daily
Aggregated Data Form
For SARI’ (refer Annex
2) – involving data both
from Medical and
Pediatric Ward,
including the respective
ICUs
• By 12:00
midnight, based
on grand total of
the daily census
generated by
nursing
personnel

9
(B) Laboratory-Based Surveillance:
• To collect 5 specimens per site per week
(i.e. 3 adults and 2 children), with the
recommendation of one specimen each
from these wards:
- Male medical ward;
- Female medical ward;
- General ICU;
- Paediatric medical ward;
- Paediatric ICU.
• The patient is systematically chosen for
testing and meets the case definition for
SARI – refer ‘Annex 4’ for the sampling
methodology
• To use the ‘Laboratory Request Form’
(Annex 6)
The personnel of Public
Health Unit:
• To collate Annex 2
from respective wards
and to send the
completed Annex 3 to
the respective State
Health Department
(JKN)
• To compile both epid
data (Annex 3) and lab
data (as per Annex 6)
for future reference
The Medical Officer /
Nursing Personnel:
• To collect the clinical
specimens as guided
by the established
procedures (Annex 5)
The laboratory personnel:
• To ensure proper
storage and transport
of the collected
samples
• To send the samples
collected to Virology
Unit of IMR, in
accordance with the
procedures established
• By 9:00 am of
the next
working day
• Continuously
• Based on the
specified
schedule
• Continously
• Weekly
District Health Office (PKD)
• To send ‘Daily Aggregated Data Form For
ILI’ (refer Annex 1) from the health clinic
to the respective State Health Department
(JKN)
• To collate copies of ‘Laboratory Request
Form’ (Annex 6) send by the health clinic
to NPHL Sungai Buloh
• To analyse local data and to monitor the
weekly trend
• To get verification from the respective
health clinic of any unusual trend recorded
and to alert the State Health Department
of such finding, if necessary
The Epid Officer &
Assistant
Environmental Health
Officer (PPKP)
• By 10:00 am,
daily
• Every week, on
Monday
• Every week, on
Tuesday
• As and when
the need arise

10
State Health Department (JKN)
• To send Annex 1 and Annex 3, gathered
respectively from PKD and hospital to the
Surveillance Sector, Disease Control
Division, MOH
• To collate the results of laboratory
investigations done by NPHL Sungai
Buloh and IMR, on the ILI and SARI
specimens; respectively
• To analyse state data and to monitor the
weekly trend
• To get verification from the respective
PKD / hospital of any unusual trend
recorded and to alert the Surveillance
Sector, Disease Control Division of such
finding, if necessary
• To incorporate the analysis within weekly
report
The Epid CDC Officer /
Surveillance Officer &
Assistant
Environmental Health
Officer
• By 11:00 am,
daily
• Every week, on
Monday
• Every week, on
Monday
• As and when
the need arise
• Every week, on
Tuesday
Surveillance Sector
,
Disease Control Division, MOH
• To collate Annex 1 and Annex 3, gathered
from JKNs nationwide
• To collate the results of laboratory
investigations done by NPHL Sungai
Buloh and IMR, on the ILI and SARI
specimens; respectively
• To analyse national data and to monitor
the weekly trend
• To get verification from the respective
JKN of any unusual trend recorded
• To prepare report and disseminate it
within the weekly bulletin
The personnel of
Surveillance Sector,
Disease Control
Division, MOH
• By 12: 00 noon,
daily
• Every week, on
Monday
• Every week, on
Monday
• As and when
the need arise
• Every week, on
Tuesday
a) Laboratory-Based Influenza Surveillance
In general, clinical specimens and epidemiological data should be collected in a
manner that minimizes bias and best represents the population under
surveillance. Hence, based on the ability of the health care facility to process,
store and transports specimens, as well as the capacity of the relevant
laboratories to process, store and test the samples in a timely manner – the
number of patients to be sampled for laboratory testing was decided upon, as the
following:

11
• From identified health clinics (i.e. the sentinel sites for ILI): To collect 5
specimens per site per week (i.e. 3 adults and 2 children) by doctors or
trained medical personnel;
• From identified hospitals (i.e. the sentinel sites for SARI): To collect 5
specimens per site per week (i.e. 3 adults and 2 children) by doctors or
nursing personnel, with the recommendation of one specimen each from
these wards:
- Male medical ward;
- Female medical ward;
- General ICU;
- Paediatric medical ward;
- Paediatric ICU.
Specimens Collection
Specimens should preferably be taken before commencement of anti-viral
medication. The time between the onset of illness and specimen collection
should be recorded on the laboratory request form.
Selected patients should fulfil the following criteria in order to be tested:
• Meet the clinical case definition for ILI or SARI; and
• The onset of symptoms falls within 10 days of sample collection.
Although informed consent from the patient is not considered necessary for
routine surveillance, a verbal explanation of the reason for specimen
collection as well as how the specimen will be used, should be given to each
patient.
A variety of specimens are suitable for influenza virus detection and isolation.
Specimens from nasal and nasopharyngeal specimens have a higher yield of
virus detection in ILI cases than oropharyngeal specimens. If patients are
intubated, endotracheal aspirates or bronchoalveolar lavages can also be
used where clinically indicated and may have a higher yield than upper
respiratory specimens in these severe cases.
The proposed sampling methodology (as per ‘Annex 4’) and the method for
specimen collection (as per ‘Annex 5’) should be adhered to. The following
are the recommended specimens to be collected from ILI and SARI case,
respectively:

12
a)
Source: ILI Case
(to collect either one of the recommended specimens)
Type of specimen Container Transport
Media
Transportation
Nasopharyngeal swab - *VTM Transport to the
designated
laboratories at
2
o
-8
o
C within 48
hours after
collection
Throat swab
Sputum Sterile
container
-
*VTM: Viral transport media
b)
Sourc
e: SARI Case
(to collect either one of the recommended specimens)
Type of specimen Container Transport
Media
Transportation
Nasopharyngeal swab - *VTM Transport to the
designated
laboratories at
2
o
-8
o
C within 48
hours after
collection
Throat swab
Nasopharyngeal aspirate
Sterile
container -
Bronchoalveolar lavage
(BAL)
Tracheal aspirate
Endotracheal tube
aspiration
*VTM: Viral transport media
Materials required for specimen collection:
i. Personal protective equipment (PPE):
• Standard precautions should always be followed (i.e. hand hygiene,
and barrier protections applied appropriately).
• The use of PPE will depend on the setting (outpatient versus
hospital) and on the severity of symptoms; outpatient personnel may
wear gloves and surgical mask to take a swab from an ILI case while
a hospital personnel taking a swab from a SARI case may wear
gloves, surgical mask and gown.
ii. Swabs:
• Use only sterile dacron, rayon or polyester fibre swab.
• Calcium alginate or cotton swabs, or swabs with wooden stick
should not be used because they may contain substances that
inactivate some viruses and inhibit PCR testing.
iii. Tongue depressor – for the collection of throat swabs.

13
iv. Viral transport media (VTM) :
• To place the nasopharyngeal or throat swab immediately after
collection.
• These should be readily available and be pre-positioned at sentinel
sites for the collection of specimens from cases of ILI and SARI
respectively.
v. Sterile container – to keep the following specimens; i.e. sputum,
nasopharyngeal aspirate, bronchoalveolar lavage (BAL), tracheal
aspirate and endotracheal tube aspiration.
vi. The completed laboratory request form and packaging materials for
transport (e.g. biohazard plastic bag, ice packs and cool box).
Specimens Storage, Packaging & Transport
The Steps
Place the collected sample in sterile
container or VTM [for throat or
nasopharyngeal (NSP) swab].
Sample in sterile
container
Throat / NSP swab
in VTM
Label the sample with:
• Patient’s name;
• Patient’s ID number;
• Sample type;
• Date of sample collection.
Fill in the laboratory request form
Refer ‘Annex 6’.
The label

14
The Steps
Place sample individually in a
biohazard plastic bag.
1 sample / plastic bag
Put the sample into cool box with 3
units of ice packs (i.e. 1 unit at the
bottom of the cool box and 2 units at
both sides of the samples). Place
some absorbent material to protect
the container from high impact or
unforeseen rough handling of the
cool box.
Seal the cool box.
Place the laboratory request form in
a plastic bag and paste on top of the
cool box.
Transport the sample to NPHL
Sungai Buloh / IMR, respectively at
2
o
to 8
o
C within 48 hours after
collection. All samples must be sent
to the sample receiving counter of
the respective laboratory.
Specimens Testing
Laboratory testing for the detection and subtyping of influenza viruses in
respiratory specimens has relied for decades upon the isolation of influenza
viruses in eggs and later cell culture followed by haemagglutination inhibition
assay (HAI) using the WHO CDC reagent kit supplied annually to National
Influenza Centres (NICs). This has the advantage that many viruses are
available to WHO for vaccine strain selection. During the past decade, the
majority of laboratories started to use molecular detection techniques to
detect and subtype influenza viruses. Most widely used is RT-PCR on real-
time PCR platforms and many laboratories gained important experience
during the Pandemic (H1N1) 2009.
Place sample
individually
Ice packs
Laboratory
request form
Address of
MKAK / IMR
Seal the
cool box

15
Briefly, the type of tests done and the laboratory turnaround time (TAT) are
shown below:
Type of specimen Type of test Laboratory TAT
Nasopharyngeal swab
•
Virus isolation
• Real time RT-PCR
•
21 days
• 7 days
Throat swab
Sputum
•
Virus isolation
• Real time RT-PCR
• Immunofluorescence
antibody test (IFAT)
•
21 days
• 7 days
• 5 days
Nasopharyngeal aspirate
Bronchoalveolar lavage
(BAL)
Tracheal aspirate
Endotracheal tube
aspiration
In conclusion, the flow chart of clinical specimen for influenza surveillance is
summarized in ‘Figure 2’.

16
Figure 2: Flow Chart of Clinical Specimen Management for Influenza Surveillance
Sentinel sites for ILI / SARI:
To collect the specified numbers of specimen as guided by the proposed sampling
methodology (Annex 4) and the established procedure (Annex 5)
The respective laboratories of the s
entinel sites:
• To ensure proper storage and transport of the collected specimens
• To send the specimens collected to designated laboratories (i.e. MKAK Sungai
Buloh for the ILI specimens and Virology Unit of IMR for SARI specimens)
MKAK Sungai Buloh / Virology Unit of IMR
:
To perform the indicated tests on the specimens received
To report as and when result are
available to:
• The sentinel sites of ILI /
SARI, respectively
• Surveillance Section, Disease
Control Division, MOH
To send the virus isolates to
WHO Collaborating Centre for
Reference and Research on
Influenza for further
characterization of the virus in a
timely manner

17
7. DATA ANALYSIS AND REPORTS
Data analysis will describe the distribution of cases over time, case by age category
and cases by local surveillance level. The laboratories involved will record the
frequency and percentage by positive viruses by type and strain. The following
parameters should be used for the analysis of influenza surveillance data:
a) ILI Surveillance Analyses By Epidemiologic Week
• Proportion of ILI cases per total consultations;
• Proportion of ILI cases per total consultations by age category;
• Proportion of ILI cases testing positive for influenza and other respiratory
viruses per the total number of ILI cases.
b) SARI Surveillance Analyses By Epidemiologic Week
• Proportion of SARI cases per total hospitalizations;
• Proportion of SARI cases per total hospitalizations by age category;
• Proportion of SARI cases testing positive for influenza and other
respiratory viruses per the total number of cases tested
Taking into consideration the revision which took place onto the Malaysia Influenza
Surveillance System (MISS), the new weekly threshold can only be calculated for the
above parameters after five years of conducting surveillance using the new
approach. This will also aid in the determination of the influenza seasonality.
Regular dissemination of surveillance data reports can lead to the creation of a
group of informed, committed local professionals who by use of timely data can act
as powerful advocates for respective interventions within the framework of national
recommendations. As a result, influenza surveillance reports should regularly be
disseminated to public health officials, health care professionals, policymakers and
the general public in order to increase public awareness of influenza and compliance
with recommended measures of prevention and control.
All influenza surveillance data collected should also be regularly analysed and
reported back to various players participating in the influenza surveillance system in
order to:
• Allow for monitoring of the influenza season;
• Guide appropriate public health action;
• Sustain the reporting interest.

18
8. THE ROLES AND RESPONSIBILITIES
This section describes general roles and responsibilities of the core personnel within
the national influenza surveillance system. Strong communication and close
coordination among sentinel sites, District Health Offices, State Health Departments,
the respective laboratories (i.e. IMR and NPHL Sungai Buloh) and Disease Control
Division, is essential for an efficiently functioning influenza surveillance system.
a) Sentinel Sites, District Health Offices & State Health Departments
Each level should designate a focal point that may be a person or persons
responsible for the routine surveillance operations. The designated focal point(s)
should assure that:
• Case definitions are known and adhered to;
• Any sampling strategies are being adhered to in as unbiased a manner as
possible;
• Respiratory specimens are collected appropriately from patients meeting
the case definitions and are packaged, stored and transported to the
designated laboratory according to the procedure established;
• All data collection forms are filled out completely and accurately;
• Epidemiologic data are appropriately managed and transmitted along the
order in a timely manner;
• Regular monitoring of surveillance resources is undertaken to maintain
adequate supplies for sustaining the routine functions of surveillance;
• Timely feedback and updates of the current influenza situation are
provided to clinicians and other personnel participating in the surveillance
activities.
b) Disease Control Division, MOH
The Surveillance Sector, Disease Control Division as the national coordinator of
the influenza surveillance program should be responsible for:
• Selection of appropriate sentinel sites;
• Decisions to maintain or discontinue specific sentinel sites;
• Decisions about surveillance strategies, techniques and epidemiological
data collection;
• Assuring that sentinel sites, District Health Offices and State Health
Departments have the necessary epidemiologic data collection
instruments and that mechanisms for routine transmission of these forms
(whether electronic or paper-based) are available to and well understood
by, the relevant parties involved in the surveillance activity;

19
• Maintaining a national surveillance database and assuring linkage
between epidemiological and virological data;
• Assuring that the data collected from the sentinel sites is analysed in a
timely and appropriate manner;
• Preparing and disseminating a weekly influenza report to relevant
stakeholders and players participating in the surveillance activities;
• Providing initial and refresher training to the sentinel sites including:
- Training on adherence to case definitions and clinical specimen
collection;
- Training on appropriate infection control measures and personal
protective equipment (PPE) usage, specimen storage and transport,
epidemiologic data collection, data reporting procedures and practical
uses of surveillance data.
• Developing and implementing a process to routinely monitor the influenza
surveillance system, including the development of performance indicators
and a plan for regular auditing through site visits.
c) The Respective Laboratories (i.e. NPHL Sungai Buloh and IMR)
The designated virological focal point from both laboratories should be
responsible for:
• Providing technical support and guidance to sentinel sites on appropriate
specimen collection, packaging, storage and transport;
• Assuring that sentinel sites have appropriate sample collection materials,
PPE and laboratory supplies to collect, store and transport specimens;
• Receiving, registering and storing specimens from cases of ILI and SARI
from sentinel sites;
• Consolidating and analysing national laboratory data for weekly reports;
• Reporting weekly laboratory data to relevant stakeholders and players
participating in the surveillance activities;
• Performing preliminary antigenic and followed by genetic characterization
of the influenza virus isolates grown at the facility;
• Timely submission of the influenza virus isolated to WHO Collaborating
Centre (via IMR) for further characterization of the virus;
• If any viruses cannot be subtyped using the WHO reagent kit, the
laboratories should notify WHO and immediately send the virus isolate to
the WHO Collaborating Centre for further analysis;
• Maintaining a database of specimens with timely entry of the laboratory
results;
• Archiving and storing original clinical specimens at -70
o
C or in liquid
nitrogen for at least one year;

20
• Participating in WHO Global External Quality Assessment Project for
molecular detection of influenza viruses, as well as in regional
programmes when available;
• Developing national diagnostic standards and assays that are periodically
validated, providing training in their use by other laboratories and
organizing routine quality assurance programs (proficiency testing);
• Monitoring specimen quality and timeliness associated with sample
submission and provision of feedback to sentinel sites to improve
specimen quality;
• Conducting annual reviews of laboratory surveillance system for quality
improvement.
9. THE NATIONAL INFLUENZA SURVEILLANCE COORDINATOR
Surveillance Sector
Disease Control Division
Ministry of Health Malaysia
Level 6, Block E10, Complex E
62590 Putrajaya
Tel: 03-8883 4119 / 4141
Fax: 03-8888 6277
E-mail: ili_ survelan@moh.gov.my

21
‘ Annex 1 ’
DISEASE CONTROL DIVISION
DISEASE CONTROL DIVISIONDISEASE CONTROL DIVISION
DISEASE CONTROL DIVISION
MINISTR
MINISTRMINISTR
MINISTRY OF HEALTH
Y OF HEALTHY OF HEALTH
Y OF HEALTH
MALAYSIA
MALAYSIAMALAYSIA
MALAYSIA
DAILY AGGREGATED DATA FORM FOR INFLUENZA
DAILY AGGREGATED DATA FORM FOR INFLUENZADAILY AGGREGATED DATA FORM FOR INFLUENZA
DAILY AGGREGATED DATA FORM FOR INFLUENZA-
--
-LIKE ILLNESS (ILI)
LIKE ILLNESS (ILI)LIKE ILLNESS (ILI)
LIKE ILLNESS (ILI)
(For ILI Sentinel Site / Health Clinic Use Only)
Clinic
:
District
:
State
:
Date
:
ILI case definition: An acute respiratory infection with measured fever of ≥ 38
o
C and cough with
onset within the last 10 days.
<10
years
10
to
19
years
20 to 59
years
≥ 60
years
Total
Number of
ILI Cases
Total
OPD Attendances
Name of Reporting Personnel: …………………………………………... Signature: ….………………….............…
Designation: …………………………………………………………........ Date: ………………………….............…
NOTE:
• Taking into consideration the work process involved in capturing data at the sentinel sites, it is
recommended for a diagnosis of upper respiratory tract infection (URTI) to be used as the proxy for
ILI case selection
• All completed form must reach the respective District Health Office by 9:00 am the next day

22
‘ Annex 2 ’
DISEASE CONTROL DIVISION
DISEASE CONTROL DIVISIONDISEASE CONTROL DIVISION
DISEASE CONTROL DIVISION
MINISTRY OF HEALTH
MINISTRY OF HEALTHMINISTRY OF HEALTH
MINISTRY OF HEALTH
MALAYSIA
MALAYSIAMALAYSIA
MALAYSIA
DAILY AGGREGATED DATA FORM FOR
DAILY AGGREGATED DATA FORM FOR DAILY AGGREGATED DATA FORM FOR
DAILY AGGREGATED DATA FORM FOR SEVE
SEVESEVE
SEVERE ACUTE RESPIRATORY
RE ACUTE RESPIRATORY RE ACUTE RESPIRATORY
RE ACUTE RESPIRATORY
INFECTION (SARI
INFECTION (SARIINFECTION (SARI
INFECTION (SARI)
))
)
(For SARI Sentinel Site i.e. Designated Wards Use Only)
Ward
:
Medical / Pediatric
/ General ICU / Pediatric ICU
*
*Please choose one of the above
Hospital
:
State
:
Date
:
SARI case definition: An acute respiratory infection with history of fever or measured fever of ≥ 38
o
C
and cough with onset within the last 10 days and requires hospitalization.
Paediatric Patients
(< 13 years)
Adult Patients
(≥ 13 years)
Total
Number of
SARI Cases
(New Admission)
Name of Reporting Personnel:…………………………………………... Signature: ….………………….............…
Designation: …………………………………………………………........ Date: ………………………….............…
NOTE:
• Taking into consideration the work process involved in capturing data at the sentinel sites, it is
recommended for a diagnosis of pneumonia, bronchitis or bronchiolitis to be used as the proxy for
SARI case selection
• All completed form must reach the respective State Health Department (via the Public Health Unit of the
hospital) by 9:00 am the next day

23
‘ Annex 3 ’
DISEASE CONTROL DIVISION
DISEASE CONTROL DIVISIONDISEASE CONTROL DIVISION
DISEASE CONTROL DIVISION
MINISTRY OF HEALTH
MINISTRY OF HEALTHMINISTRY OF HEALTH
MINISTRY OF HEALTH
MALAYSIA
MALAYSIAMALAYSIA
MALAYSIA
DAILY AGGREGATED DATA FORM FOR
DAILY AGGREGATED DATA FORM FOR DAILY AGGREGATED DATA FORM FOR
DAILY AGGREGATED DATA FORM FOR SEVERE ACUTE RESPIRATORY
SEVERE ACUTE RESPIRATORY SEVERE ACUTE RESPIRATORY
SEVERE ACUTE RESPIRATORY
INFECTION (SARI
INFECTION (SARIINFECTION (SARI
INFECTION (SARI)
))
)
(For SARI Sentinel Site i.e. The Public Health Unit Use Only)
Hospital
:
State
:
Date
:
SARI case definition: An acute respiratory infection with history of fever or measured fever of ≥ 38
o
C
and cough with onset within the last 10 days and requires hospitalization.
Paediatric Patients
(< 13 years)
Adult Patients
(≥ 13 years)
Total
Number of
SARI Cases
(New Admission)
Total
All
-
Cause
Hospitalizations
(New Admission)
Name of Reporting Personnel: …………………………………………... Signature: ….………………….............…
Designation: ………………………………………………..…………........ Date: ………………………….............…
NOTE:
• Taking into consideration the work process involved in capturing data at the sentinel sites, it is
recommended for a diagnosis of pneumonia, bronchitis or bronchiolitis to be used as the proxy for
SARI case selection
• All completed form must reach the respective State Health Department by 9:00 am

24
‘ Annex 4 ’
SAMPLING METHODOLOGY
Laboratory testing on all patients seen in an outpatient department with ILI or admitted to a
sentinel hospital for SARI would produce data with the least bias. However, this is not likely
to be feasible for most sites.
Patient selection for testing should be done in such a way as to minimize bias.
A systematic approach to case selection that does not leave the choice of cases to test
(other than to determine that the case meets the definition) and that covers different times of
the day and different days of the week is likely to be the most pragmatic, while providing
reasonably representative data.
Several sampling methodologies are proposed below and they are presented in order of
increasing potential for bias in case selection:
a) Interval Sampling
A straightforward method that would yield data similar to that from a random sampling
strategy would be to select every Nth case at the sentinel site. For example, every 5th
(or 7th or 10th) patient who meets the case definition would be selected for testing and
data collection. Some foreknowledge of the volume of cases at the sentinel site is
required so that the appropriate sampling interval can be selected. This type of
sampling would likely require a designated person to oversee case selection on a daily
basis and it is somewhat complicated.
b) Alternate Day Sampling
A second systematic sampling method is to select all patients who meet the case
definition presenting to a facility on a certain day or days of the week. This can reduce
the logistical challenges of surveillance by confining laboratory specimen and data
collection efforts to a single day. In order to remove the bias introduced by differences
in health-seeking behaviour associated with particular days of the week, the day on
which cases are selected should be systematically alternated from week to week. A
variant of alternate sampling is sequentially sampling whereby the personnel identify
case patients during specific consecutive days of the week (e.g. Monday, Tuesday and
Wednesday).
c) Modified Convenience Sampling
A third approach involves testing the first X number of cases that meet the case
definition. If this method is used, the time frame for selection should be systematically
rotated to take into account local health-seeking behaviours such as differential use of
evening or weekend clinics. For example, a site might select the first 2 cases from the
morning clinic session (or admissions to hospital, in the case of SARI), the afternoon
clinic, and the evening clinic on each day of the week, including weekends. Care would
need to be taken not to introduce systematic biases in the types of cases selected.

25
‘ Annex 5 ’
METHOD FOR COLLECTION OF RESPIRATORY SPECIMENS
a) Collection of Nasopharyngeal Swab
• For nasopharyngeal swab collection, the patient’s head should be inclined
from the vertical as shown below for proper specimen recovery.
• Insert swab into one nostril until a slight resistance is met.
• Rotate swab over surface of posterior nasopharynx 2 to 3 times. Leave
the swab in place for a few seconds to absorb secretions.
• Repeating procedure for the second nostril will deliver optimal combined
sample. Withdraw swab and repeat procedure in other nostril with the
same swab.
• Remove swab and place the swab immediately into a sterile vial
containing VTM.
• Break the applicator stick off near the tip to permit closure of the lid.
Plastic swab handles usually have a weak point in them to allow them to
be broken off for insertion into a specimen tube. Others have a handle
made of a brittle plastic that will snap easily. If the shaft cannot easily be
broken off so that it is short enough to fit into a small tube, it will have to
be cut. To do this:
- Cut the shaft with a sterile scissors, taking care not to touch the tip;
- Allow the tip to slide into the VTM and then cap the tube (do not let cut
portions of the plastic bag fall into the tube).
• Label the specimen container (the cap should not be marked, as it may
get switched during handling) with:
- Patient’s name;
- Patient’s ID number;
- Sample type;
- Date of sample collection.

26
• Send the specimen to NPHL Sungai Buloh / IMR, respectively at 2
o
to 8
o
C
within 48 hours after collection.
b) Collection of Throat Swab
• Hold the swab and with a sweeping motion, swab the posterior
pharyngeal wall and tonsillar pillars (refer the figure below):
- Have the subject to say ‘aahh’ to elevate the uvula;
- Hold the tongue out of the way with a tongue depressor (Note: this
procedure can induce the gag reflex);
- Avoid swabbing the soft palate and do not touch the tongue with the
swab tip.
• Place the swab immediately into a sterile vial containing VTM.
• Break the applicator stick off near the tip to permit closure of the lid.
Plastic swab handles usually have a weak point in them to allow them to
be broken off for insertion into a specimen tube. Others have a handle
made of a brittle plastic that will snap easily. If the shaft cannot easily be
broken off so that it is short enough to fit into a small tube, it will have to
be cut. To do this:
- Cut the shaft with a sterile scissors, taking care not to touch the tip;
- Allow the tip to slide into the VTM and then cap the tube (do not let cut
portions of the plastic bag fall into the tube).
• Label the specimen container (the cap should not be marked, as it may
get switched during handling) with:
- Patient’s name;
- Patient’s ID number;
- Sample type;
- Date of sample collection.
• Send the specimen to NPHL Sungai Buloh / IMR, respectively at 2
o
to 8
o
C
within 48 hours after collection.

27
c) Collection of Sputum
Sputum is the mucous or phlegm coughed up from the lungs. It is not saliva
or mucous from the back of the throat.
• For best results, obtain the sample first thing in the morning. If the subject
just had his breakfast, wait at least an hour after he's eaten before trying.
Before initiating the procedure, describe it well to the subject.
• To get a good sample, instruct the subject to take at least three deep
breaths, then force out a deep cough. Explain that deep breathing helps
loosen secretions and bring them to the back of the throat. Emphasize the
importance of bringing up sputum, the thick secretions from the lungs,
rather than expectorating saliva, the thin secretions from the mouth.
• Once the subject is comfortable with his part in the procedure, set up the
equipment needed. Prepare a sterile specimen cup with a tight-fitting cap,
the appropriate label, gloves, surgical mask and goggles.
• Be ready with an aerosol of 10% sodium chloride or sterile water on hand
to administer via nebulizer if needed. This can help loosen tenacious
secretions.
• Position the subject in a chair or on the side of the bed. If he's unable to
sit up on his own, place him in a high-Fowler's position. Remove his
dentures, if he has them.
• Next, have the subject rinse his mouth with plain water so that he doesn't
contaminate the sputum being coughed up with the bacteria in his mouth.
But don't allow him to brush his teeth or use mouthwash. Doing so could
kill bacteria in the sputum, rendering it useless.
• Get ready by donning the gloves, surgical mask and goggles. Uncap the
container, but avoid touching the inside to ensure that it's sterile. Then,
have the subject perform the deep breaths and cough as instructed,
expectorating the sputum into the container.
• Encourage the subject to continue coughing until adequate sample is
collected. However, if he has trouble bringing up secretions, have him
breathe into the nebulizer and try again.
• Once sufficient specimen collected, securely cap the container. Remove
and discard the gloves and wash hands thoroughly. Allow the subject to
rinse out his mouth and provide a tissue.
• Send the specimen to NPHL Sungai Buloh / IMR, respectively at 2
o
to 8
o
C
within 48 hours after collection.
NOTE: Method for samples collection not documented here are those which
will only performed by experienced personnel.

28
SISTEM SURVELAN INFLUENZA KEBANGSAAN
BORANG PERMOHONAN UJIAN MAKMAL
(Sampel ILI Dihantar Ke MKAK Sungai Buloh & Sampel SARI Dihantar Ke Unit Virologi, IMR)
No. Rujukan Makmal: (IMR / RES / 20 / ) (MKAK / RES / 20 / )
A. MAKLUMAT PESAKIT
Negeri:
Hospital / Klinik Kesihatan: Wad:
Nama Pesakit: No. Kad Pengenalan / Passport:
R/N: Warganegara: Umur: Jantina: L / P
B. MAKLUMAT KLINIKAL
Gejala
Tandakan (
√
) di ruangan
berkenaan
Tarikh mula
Demam ≥ 38
o
C / sejarah demam beberapa hari sebelumnya
Batuk
Dapatan X-Ray (sekiranya berkenaan): 
C. MAKLUMAT SPESIMEN KLINIKAL
Jenis Spesimen
Tandakan (
√
) di
ruangan berkenaan
Tarikh
diambil
Tarikh
dihantar
Pengambil
Sampel
Nasopharyngeal (NP) swab
(Tandatangan & Cop)
Throat swab
Nasopharyngeal aspirates
Bronchoalveolar lavage (BAL)
Tracheal aspirate
Endotracheal tube aspiration
Lain-lain (sila nyatakan:
)
NOTA: Sampel palitan (swab) mesti dimasukkan ke dalam bekas yang mengandungi Viral Transport Media (VTM) dan sampel lain dimasukkan ke dalam bekas steril kosong.
Kesemua jenis sampel mesti disimpan pada suhu 2
o
-8
o
C sejurus diambil dan tiba di makmal yang dikenalpasti dalam tempoh sekurang-kurangnya 48 jam selepas pengambilan.
CATATAN:
..
D. MAKLUMAT PEMOHON
E. MAKLUMAT MAKMAL T
RANSIT
* (sekiranya berkenaan)
Tandatangan & Cop Pegawai:
Tandatangan & Cop Pegawai:
No. Telefon: No. Telefon:
*
Makmal Transit:
Makmal dimana
spesimen
dihantar untuk tujuan pengumpulan sebelum ia seterusnya dihantar ke
MKAK
Sungai Buloh / Unit Virologi, IMR
F
. UNTUK KEGUNAAN MAKMAL
Kaunter Penerimaan Sampel
Makmal
Tarikh spesimen diterima: Tarikh spesimen diterima:
Suhu:
o
C Suhu:
o
C
Jenis spesimen: Jenis spesimen:
Status: Sampel Diterima / Sampel Ditolak* Status: Sampel Diterima / Sampel Ditolak*
* Sekiranya spesimen ditolak, sila nyatakan sebab: ...
CATATAN:
Tandatangan & Cop Pegawai:
Tandatangan & Cop Pegawai:
Sebarang kemusykilan, sila hubungi:
• Makmal Kesihatan Awam Kebangsaan (MKAK) Sungai Buloh, Selangor (u.p. Makmal Isolasi Virus): 03-6126 1200 / 1325
• Unit Virologi, Institut Penyelidikan Perubatan (IMR): 03-2616 2671
‘ Annex 6 ’